2024-11-13 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis:

**1.  Performance Comparison:**

Eli Lilly and Co. (LLY) has outperformed the S&P 500 (VOO) significantly over the past years. The cumulative return for LLY is 924.94%, while the S&P 500 has returned 179.25%. This results in a **745.69%** difference, positioning LLY at the **78.88%** percentile of its historical performance relative to the S&P 500.

**Alpha and Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 30.4% | 18.8% | -8.0% | 0.8 | 80.2 |
| 2016-2018  | 50.8% | 18.8% | 18.5% | 0.7 | 109.8 |
| 2017-2019  | 89.5% | 16.8% | 37.8% | 0.7 | 124.8 |
| 2018-2020  | 113.2% | 21.9% | 65.8% | 0.7 | 160.3 |
| 2019-2021  | 154.6% | 21.9% | 54.6% | 0.7 | 262.2 |
| 2020-2022  | 190.4% | 21.9% | 166.8% | 0.7 | 347.3 |
| 2021-2023  | 266.0% | 18.6% | 231.1% | 0.5 | 553.4 |
| 2022-2024  | 210.0% | 19.0% | 179.6% | 0.6 | 790.2 |

The analysis highlights a consistent outperformance of LLY compared to the market, with a positive alpha indicating a strong track record of exceeding benchmark returns. The beta, consistently below 1, suggests a lower volatility compared to the market.


**2.  Recent Price Fluctuation:**

* **Closing price:** 818.86 (Last-market: 819.23)
* **5-day Moving Average:** 811.33
* **20-day Moving Average:** 860.88
* **60-day Moving Average:** 901.09

The recent price action suggests a short-term downtrend with the price trading below all three moving averages. 

**3.  Technical Indicators:**

* **RSI:** 30.91 - Indicates oversold territory, suggesting potential for a bounce back.
* **PPO:** -0.4 - Suggests bearish momentum.
* **Relative Divergence:** -13.35 (Short-term bearish) - Indicates a downward trend in the relative price strength.
* **Expected Return:** 116.18% - High expected return, suggesting potential for outperformance over the long term.

**4.  Recent Earnings and Outlook:**

| Date         | EPS  | Revenue  |
|--------------|------|----------|
| 2024-10-30 | 1.08 | $11.44B |
| 2024-08-08 | 3.29 | $11.30B |
| 2024-04-30 | 2.49 | $8.77B |
| 2023-11-02 | -0.06 | $9.50B |
| 2024-10-30 | -0.06 | $9.50B |

**Most recent earnings (2024-10-30):** 

* **EPS:** 1.08
* **Revenue:** $11.44B

The company surpassed analyst expectations for both EPS and revenue for the most recent quarter. This indicates a positive trend in the company's financial performance.

**5.  Financial Information:**

**1) Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|----------------|
| 2024-09-30 | $11.44B | 81.02%         |
| 2024-06-30 | $11.30B | 80.80%         |
| 2024-03-31  | $8.77B  | 80.91%         |
| 2023-12-31  | $9.35B  | 80.88%         |
| 2023-09-30  | $9.50B  | 80.42%         |

The company demonstrates consistent profitability, maintaining a high profit margin across quarters. This indicates strong revenue generation and efficient cost management.

**2) Capital and Profitability:**

| Quarter      | Equity | ROE       |
|--------------|--------|------------|
| 2024-09-30 | $14.24B | 6.81%      |
| 2024-06-30 | $13.56B | 21.88%     |
| 2024-03-31  | $12.81B | 17.51%     |
| 2023-12-31  | $10.77B | 20.33%     |
| 2023-09-30  | $11.22B | -0.51%     |

ROE fluctuates but generally remains positive, indicating strong shareholder returns.

**6.  News and Recent Issues:**

* **Recent Earnings News:** Eli Lilly and Co. (LLY) beat analysts' earnings expectations for the third quarter of 2024, exceeding both EPS and revenue projections.
* **Recent Market Outlook:** Analyst opinions on LLY are generally positive. According to FINBOLD, the consensus rating is "Buy," with a median price target of $900. 
* **Performance Highlights:** The company's strong recent earnings performance, driven by the growth of its diabetes and obesity drug Mounjaro, has been a key driver of its stock price gains.

**7.  Summary:**

* Eli Lilly and Co. (LLY) has consistently outperformed the market, showcasing strong growth and profitability.
* Recent price action suggests a short-term downtrend, but technical indicators suggest potential for a rebound.
* The company's strong financial performance and positive outlook provide a compelling case for long-term investment. 

**Overall, LLY presents a compelling investment opportunity for investors seeking growth and stability. The company's strong track record, positive outlook, and high expected return suggest potential for continued outperformance over the long term.**